Here, we document a 53-year-old male with HER2-amplified rectal cancer and brain metastases, treated with Trastuzumab Deruxtecan (T-Dxd, 5.4 mg/kg) plus bevacizumab (7.5 mg/kg) every three weeks as third line therapy. The gene discussed is ERBB2; the disease is rectal cancer.